SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 208.62 |
Enterprise Value ($M) | 256.92 |
Book Value ($M) | -60.24 |
Book Value / Share | -0.97 |
Price / Book | -3.46 |
NCAV ($M) | -60.73 |
NCAV / Share | -0.98 |
Price / NCAV | -3.44 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -3.55 |
Return on Assets (ROA) | -2.03 |
Return on Equity (ROE) | n/a |
Liquidity (mrq) | |
---|---|
Quick Ratio | 1.77 |
Current Ratio | 1.77 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 27.71 |
Assets | 28.20 |
Liabilities | 88.44 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | -38.07 |
Net Income | -41.07 |
Earnings Per Share Basic And Diluted | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -32.97 |
Cash from Investing | 0.00 |
Cash from Financing | 40.03 |
(click for more detail) |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
29,390 | 150,545 | 19.52 | |
52,296 | 246,820 | 21.19 | |
29,987 | 107,319 | 27.94 | |
35,116 | 48,295 | 72.71 | |
58,987 | 66,054 | 89.30 | |
(click for more detail) |
Similar Companies | |
---|---|
FLGC – Flora Growth Corp. | FTLF – FitLife Brands, Inc. |
FWBI – First Wave BioPharma, Inc. | GDTC – CytoMed Therapeutics Limited |
GHSI – Guardion Health Sciences, Inc. |